CAM
KALA icon

ClariVest Asset Management’s KALA BIO KALA Stock Holding History

ClariVest Asset Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13
Closed -$225K – 773
2020
Q4 		$225K Hold
13
– – 0.01% 482
2020
Q3 		$251K Buy
13
+4
+44% +$91.9K 0.01% 434
2020
Q2 		$244K Buy
+9
New +$255K 0.01% 506

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClariVest Asset Management's KALA Position: Q1 2021 in Review

ClariVest Asset Management sold out of KALA BIO (KALA) in Q1 2021, closing a stake of 13 shares — an estimated $225K sold.

ClariVest Asset Management first reported a position in KALA in Q2 2020 and held it in 3 quarters. The position peaked at $251K in Q3 2020. 106 funds tracked by Wall St. Rank hold KALA as of Q1 2021.

  • ClariVest Asset Management reported no remaining KALA BIO position as of Q1 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 13 KALA BIO shares in Q1 2021, an estimated $225K.
  • ClariVest Asset Management first reported a position in KALA BIO in Q2 2020 and held it in 3 quarters.
  • ClariVest Asset Management's KALA BIO position peaked at $251K in Q3 2020.
  • 106 funds tracked by Wall St. Rank held KALA BIO as of Q1 2021.

Based on ClariVest Asset Management's 13F filing for Q1 2021, filed 13 May 2021.